



IMMUNOTHERAPIES – ADVANCES AND ADAPTIONS
11th International Congress

SEPSIS^{11th}
UPDATE
2023 Sept 06–08
Weimar

FINAL PROGRAM



PREFACE	4
GENERAL INFORMATION	6
ENDORSEMENTS	8
SCHEDULE AT A GLANCE	10
PROGRAM	16
Wednesday	17
Thursday	28
Friday	35
SPEAKERS & CHAIRS	41
COMPANIES & EXHIBITORS	53
ABSTRACTS	60

Imprint:

Deutsche Sepsis-Gesellschaft e.V.
Waldenserstraße 2-4
10551 Berlin

Design: © Lindgrün GmbH | 2023
www.lindgruen-gmbh.com

WELCOME TO THE 11TH WEIMAR SEPSIS UPDATE “ADVANCES AND ADAPPTIONS”

Dear colleagues,

In the past 36 months, the critical care community has been confronted with the Corona pandemic, which has added SARS-CoV-2 as a new pathogen to the diverse range of sepsis pathogens. This has accelerated vaccine and drug development in a way that has never been seen before. SARS-CoV-2 has shown us once again how different the specific (adaptive) immune response to a specific pathogen can be and how differently organ dysfunctions may develop as a result.

In contrast to other sepsis pathogens, the immunotherapy of severe COVID-19 has reached important advances, being the first sepsis pathogen in which a strong level of evidence permits the recommendation of immunotherapy. Apparently ineffective or even harmful therapeutic approaches based on evidence extrapolated from other sepsis conditions may be appropriate in the face of novel pathogens with a different immunopathology. Indeed, the initial expert opinion to avoid corticosteroids and IL-6 receptor antagonists (IL-6ra) as an immunomodulatory treatment for COVID-19, while later on, they became standard-of-care (SoC), underscores the importance of obtaining solid evidence based on robust clinical trials. These advances provide impetus to better understand the effects of IL-6 on different compartments and pathways, i.e. the endothelium, complement activation, and coagulation which might improve management of other forms of sepsis in the future.

Another lesson from COVID-19 clinical research is that traditional trial designs are not well-suited for efficient evaluation of differential treatment effects in different patient groups. Most of the evidence supporting SoC options have come from adaptive platform trials, such as RECOVERY or REMAP-CAP. These designs are more flexible for the evaluation of combinations of therapies and evaluation of effects across different subgroups.

However, as pointed out in a recent review by van de Veerdonk et al. (Nat Med 2022, 28, 39–50), the host response to SARS-CoV-2 - and other sepsis pathogens - is complex, characterized by a plethora of pathways that can be both beneficial and deleterious. Not surprisingly, agents that modify these pathways can be beneficial for some patients and ineffective or even harmful for others. The way forward is to perform trials based on robust biomarkers, so that patients that are more likely to benefit from a given treatment will receive it.

The meeting will give outstanding researchers the opportunity to report on the latest advances in immunomodulatory approaches to the adaptive immune response in sepsis. Get up to date on the current state of knowledge!



Frank M. Brunkhorst
Secretary General GSS

General information

Scientific Committee

M. Adamzik, MD, Bochum
F. M. Brunkhorst, MD, Jena
A. Kaasch, MD, Dusseldorf
M. Pletz, MD, Jena
M. Singer, PhD, MD, London
M. Weigand, MD, Heidelberg

Scientific Coordination

Prof. F. M. Brunkhorst
Secretary General of the German Sepsis Society
frank.brunkhorst@sepsis-gesellschaft.de

Congress Language

English

Organizer

weimar GmbH
Gesellschaft für Marketing,
Kongress- und Tourismusservice
UNESCO-Platz 1
99423 Weimar, Germany

CME


The meeting is certified by the
State Medical Chamber of Thuringia
with up to 23 advanced training points.

WiFi

Sepsis23

Congress Venue

congress centrum weimarhalle
UNESCO-Platz 1
99423 Weimar, Germany
www.weimarhalle.de



SCHEDULE ATA GLANCE

Endorsements

- ▶ Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS), Sydney
- ▶ Canadian Critical Care Trials Group (CCCTG), Toronto
- ▶ Center for Sepsis Control and Care (CSCC), Jena University Hospital
- ▶ Central and Eastern European Sepsis Forum (SepsEast)
- ▶ Deutsche Gesellschaft für Infektiologie (DGI)
- ▶ Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN), Berlin
- ▶ German Center for Infection Research (DZIF), Brunswick
- ▶ German Centre for Lung Research (DZL), Giessen
- ▶ European Group on Immunology of Sepsis (EGIS), Jena
- ▶ European Shock Society (ESS)
- ▶ Intensive Care National Audit and Research Centre (ICNARC), and Imperial College London
- ▶ International Forum for Acute Care Trialists (INFACT), Toronto
- ▶ Irish Critical Care Clinical Trials Network (ICCTN), Dublin
- ▶ REMAP-CAP (A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia), Utrecht
- ▶ UK Critical Care Research Group (UKCCRG)
- ▶ University Medical Center Utrecht (UMCU)

PROGRAM

Wednesday

September 6, 2023

09:00 – 12:00

Workshops (parallel sessions) 3 hrs each

WS1: Animal models in sepsis and COVID-19: reality, challenges and future directions

Small Hall

Coordination: Marcin Osuchowski, Vienna, Austria;
Tomasz Skirecki, Warsaw, Poland

- **Animal research in 2023: reality, challenges and future directions**
Marcin Osuchowski, Vienna, Austria
- **Ethics and research: rethinking animal sepsis modeling in the context of human experimental techniques**
Stephanie Krämer, Giessen, Germany
- **The ethics of analgesia in animal models of acute illnesses: controversies, needs, applicability**
Adrian Press, Jena, Germany
- **Are you sharing? Standardized banking of animal model biosamples**
Ingrid Walter, Vienna, Austria
- **CIRS-LAS Project: engaging peers to improve quality**
Astrid Enkelmann, Jena, Germany
- **animalstudyregistry.org – improving reproducibility in animal research through preregistration**
Céline Heintz, Berlin, Germany

Short oral presentations (10 min)

Hyperspectral imaging is useful to non-invasively assess septic microcirculatory disorders in a mouse model

Lucas Tichy, Heidelberg, Germany

(Wo)men & Mice – sex and age on the mouse intensive care unit

Ulrike Heinicke, Frankfurt, Germany

Bacterial polyphosphates mediate death and metabolic dysregulation during sepsis

Markus Bosmann, Mainz, Germany

Virus-induced premature cellular senescence of the lung

Stefanie Deinhard-Emmer, Jena, Germany

Comparing different sepsis scoring systems in experimental model of abdominal sepsis

Ruslan Sydoruchuk, Chernivtsi, Ukraine

WS2: European Group on Immunology of Sepsis (EGIS)[Seminar Room 2](#)

Coordination: Jesus F. Bermejo-Martin, Salamanca, Spain; Ignacio Rubio, Jena, Germany

- **The consensus molecular endotypes of sepsis**
Brendon P. Scicluna, Malta
- **Hemophagocytic Lymphohistiocytosis in critically ill patients**
Gunnar Lachmann, Berlin, Germany
- **Hypometabolism in sepsis – a translational perspective**
Sebastian Weis, Jena, Germany
- **Immune pathophysiology of chronic organ failure after sepsis**
Benjamin Glenn Chousterman, Paris, France
- **The immunomodulatory potential of Vitamin A in Candida albicans infections**
Tilman Klassert, Brunswick, Germany

Short oral presentations (10 min)**Effects of sepsis on the functional integrity of sensory neurons in mice**

Beatrice Oehler, Heidelberg, Germany

Immune cell compartmentalization and function during sepsis

Stavroula Litsiou, Jena, Germany

The Inflammasome caspase-1 pathway drives lung fibrosis in COVID-19 ARDS

Konrad Peukert, Bonn, Germany

Microbial metabolite dysregulation in obesity: A link between gut and alveolar sensing during Influenza A Virus infection

Franziska Hornung, Jena, Germany

Microglia mediate neurocognitive deficits by eliminating C1q-tagged synapses in sepsis-associated encephalopathy

Jonathan Wickel, Jena, Germany

WS3: Joint session: German Center for Infection Research and German Sepsis Society[Wing Hall 1](#)

Coordination: Andreas Peschel, Tübingen, Germany; Mathias Pletz, Jena, Germany

- **Bacteriophages as personalized anti-infective therapy –**
Annika Claßen, Cologne, Germany
- **R-NET: DZIF network for investigating multi-resistant bacterial pathogens**
Dennis Nurjadi, Lubeck, Germany
- **New antibiotics against multidrug-resistant bacteria**
Yvonne Mast, Brunswick, Germany
- **The GPR43 receptor as an experimental target for sepsis therapy**
Dorothee Kretschmer, Tübingen, Germany
- **Precision probiotics against Klebsiella pneumonia**
Till Strowig, Brunswick, Germany

Short oral presentations (10 min)**Suppression PCR-based selective enrichment sequencing (SUPSETS) for pathogen and antimicrobial resistance detection on cell-free DNA in sepsis**

Mirko Sonntag, Tübingen, Germany

Human cytomegalovirus latency is associated with reduced patient survival during sepsis

Matthias Unterberg, Bochum, Germany

A 29-mRNA host response classifier identifies bacterial infections following liver transplantation

Sebastian Decker, Heidelberg

Use of ECCO2R in *Pneumocystis jirovecii* pneumonia: elimination of CO₂, meropenem, and vancomycin

Vassilissa Govorov, Munich, Germany

WS4: Extracorporeal Life Support (ECLS) and Extracorporeal Membrane Oxygenation (ECMO) in sepsis- and COVID-19 associated ARDS

[Large Hall](#)

Coordination: Matthieu Schmidt, Paris, France;
Konstanty Szuldrzyński, Warsaw, Poland

• **ECMO in COVID-19: What are the main differences with other ARDS etiologies on ECMO?**

Martin Urner, Toronto, Canada

• **PK / PD during ECMO**

Alexander Supady, Freiburg, Germany

• **Infectious complications on ECMO**

Jordi Riera, Barcelona, Spain

• **Long-term outcomes of COVID-related ARDS on ECMO**

Konstanty Szuldrzyński, Warsaw, Poland

• **ECMO for septic shock**

Matthieu Schmidt, Paris, France

Short oral presentations (10 min)

Mass-spectrometry analysis of exhaled breath condensate in SIRS/sepsis diagnostics of mechanically ventilated patients — preliminary results

Martin Müller, Prague, Czech Republic

The concentration of apoptosis inhibitor of macrophages (AIM) protein is associated with 30-day survival in patients with COVID-19 sepsis

Dominik Ziehe, Bochum, Germany

Prognostic biomarkers in COVID-19 according to time since disease onset prior to hospitalization

Tamara Postigo, Salamanca, Spain

Long-term outcomes of septic critically ill patients with and without COVID-19 – preliminary results from the prospective Comprehensive Sepsis Center Study Dresden-Kreischa

Felix Niebhagen, Dresden, Germany

WS5: Joint session: German Society for Infectious Diseases and German Sepsis Society – Staphylococcus aureus bloodstream infection: from diagnosis to treatment

[Seminar Room 3](#)

Coordination: Achim Kaasch, Magdeburg, Germany;
Bernd Salzberger, Regensburg, Germany

• **Do all strains of *S. aureus* have the same potential to cause severe disease?**

Francois Vandenesch, Lyon, France

• **Advances in *S. aureus* pathophysiology from a clinical point of view**

Alex Soriano, Barcelona, Spain

• **Does neutropenia affect the course of *S. aureus* bacteremia?**

Siegbert Rieg, Freiburg, Germany

• **Early oral switch in *S. aureus* bacteremia – The SABATO trial**

Achim Kaasch, Magdeburg, Germany

• **Platform trial in SAB: the SNAP trial**

Marc Bonten, Utrecht, The Netherlands

Short oral presentations (10 min)

When Time to Result matters: Direct Rapid Susceptibility Testing of Sepsis Pathogens in Positive Blood cultures

Ulrike Schumacher, Ravensburg, Germany

Unveiling Mutations Causing Carbapenemase-Independent Carbapenem Resistance for Molecular Diagnostics

Sara Madzgalla, Jena, Germany

Resistance to first-line empirical antibiotic treatment in septic patients admitted to the emergency department

Leonhard Maximilian von Beck, Budapest, Hungary

Establishment of a method to measure linezolid concentration in endotracheal aspiration in critically ill patients:

A proof of concept trial

Diana Rebholz, Munich, Germany

WS6: SepsEast – Experiences with the pandemic in Central-Eastern European intensive care units

[Seminar Room 4](#)

Coordination: Jan Beneš, Pilsen, Czech Republic;
Małgorzata Mikaszewska-Sokolewicz, Warsaw, Poland

The COVID-19 pandemic in Central Eastern Europe

- **How it affected the general population**
Jan Beneš, Pilsen, Czech Republic
- **How it affected the ICU's – results of the SEARCH registry**
Miłosz Jankowksy, Kraków, Poland
- **How it affected the ICU's – secondary analyses of the SEARCH registry**
Roman Záhorec, Bratislava, Slovakia
- **Experiences from Romania**
Dorel Săndesc, Timișoara, Romania
- **Experiences from Serbia**
Radmilo J. Jankovic, Niš, Serbia

Lessons to learn

- **West vs. East – what makes the difference in outcomes?**
Zsolt Molnar, Budapest, Hungary
- **Health care policy**
Waldemar Gozdzik, Wrocław, Poland
- **Resources and staffing**
Alan Šustić, Rijeka, Croatia
- **Research development**
Mitja Lainscak, Ljubljana, Slovenia

Short oral presentations (10 min)

Rationale and design of the COSMOS Registry:

An international, prospective registry of CytoSorb® blood purification device in critically ill patients

Ricard Ferrer, Barcelona, Spain

Analysis of the use of protocols regarding futile therapy in patients with sepsis/ septic shock treated in the Intensive Care Unit in years 2017-2022

Marek Welna, Wrocław, Poland

Structural Requirements in Statutory Quality Assurance - Results of the Quality Indicator Development titled „Diagnosis, Therapy and Aftercare of Sepsis“

Stefanie Erckenbrecht, Berlin, Germany

Circulating bioactive Adrenomedullin (bio-ADM) and lactate identify hydrocortisone responders among patients with sepsis – a post hoc analysis of the HYPRESS RCT

Caroline Neumann, Jena, Germany

WS 7: Imaging infections and sepsis at different length scales – from whole organ in-vivo imaging to ultrastructure

[Seminar Room 5](#)

Coordination: Ute Neugebauer, Jena, Germany;
Verena Hörr, Bonn, Germany

- **State of the art of infection visualization in pathology**
Lina Carvahlo, Coimbra, Portugal
- **Multiparametric MRI to investigate cardiac function, hemodynamic alterations as well as renal injuries during sepsis**
Verena Hörr, Bonn, Germany
- **Imaging the onset and resolution of pulmonary inflammation**
Jan Rossaint, Munster, Germany
- **Label-free, non-destructive characterization of intracellular pathogens using Raman microscopy**
Ute Neugebauer, Jena, Germany

• **Data infrastructure to organize medical image data**

José Luis Oliveira, Aveiro, Portugal

Short oral presentations (10 min)

IMAGE-IN: A multidimensional 3D web visualizer for microscope imaging modalities

Yubraj Gupta, Aveiro, Portugal

Cloud-based system for histological image registration

Rodrigo Escobar Diaz Guerrero, Aveiro, Portugal

Unveiling *S. aureus*-Induced Bone Deformation in a Mouse Model of Chronic Osteomyelitis through Fluorescence and Raman Imaging

Shibarjun Mandal, Jena, Germany

Visualization of pathogens and host cellular damage using electron microscopy

Sandor Nietzsche, Jena, Germany

Ex vivo characterization of the intra-epithelial lymphocytes (IEL) fraction from small intestine using Raman spectroscopy

Rustam Guliev, Jena, Germany

12:00 – 13:00

Break

12:00 - 13:00 | Wing Hall 2

Press Conference

13:00 – 15:30 | Large Hall

Opening Session

Framework for future research

Chair:

Achim Kaasch, Magdeburg, Germany;

Michael Adamzik, Bochum, Germany

Opening address

Mervyn Singer, London, United Kingdom,

Patron of the German Sepsis Society

Key Note Lecture (30 min) –

European Clinical Research Alliance on Infectious Diseases (ECRAID)

Marc Bonten, Utrecht, The Netherlands

Research Awards Ceremony (20 min)

Markus Weigand, Heidelberg, Germany; Mathias Pletz,

Jena, Germany

Sepsis numbers – how much? (20+5 min)

Mervyn Singer, London, United Kingdom

Trigger tools for early sepsis identification (20+5 min)

Simon Finfer, Sydney, Australia

Adaptive platforms trials in critical care (20+5 min)

Lennie Derde, Utrecht, Netherlands

Sepsis classification systems and endotypes

(20+5 min)

John Marshall, Toronto, Canada

15:30 – 16:00

Break

16:00 – 17:20 | Large Hall

Session 1

From systems biology to personalized care

Chair:

Michael Bauer, Jena, Germany;
Peter Rosenberger, Tübingen, Germany

Promises and challenges of personalized medicine to guide ARDS therapy

Daniel F. McAuley, Belfast, United Kingdom

Compartmentalized inflammation in sepsis

Manu Shankar-Hari, Edinburgh, Scotland

Prognostic or predictive enrichment trials – will they make a difference?

Kathy Rowan, London, United Kingdom

A path to realize precision treatment of sepsis

Sachin Yende, Pittsburgh, USA

17:20 – 17:40

Break

17:40 – 19:00 | Large Hall

Session 2

Steroids

Chair:

Joseph Briegel, Munich, Germany;
Herwig Gerlach, Berlin, Germany

The HPA axis in critical illness – therapeutic implications of the evolving evidence

Greet Van den Berghe, Leuven, Belgium

Steroids for bacterial CAP

- **Pro:** Djillali Annane, Paris, France
- **Con:** Martin Kolditz, Dresden, Germany

AI to estimate individual treatment effects in septic shock

Romain Pirracchio, San Francisco, United States

19:00 | Terraces

Get-Together-Party

featuring „Septic Shockers“, Jena, Germany

Foto: Sepsis Update 2019
© Maik Schuck, Weimar GmbH



07:30 – 08:00

Sepsis Morning Rounds

My worst sepsis case

Staphylococcus aureus bacteremia | Wing Hall 1

Reimer Riessen, Tübingen, Germany

Abdominal surgery | Wing Hall 2

Wolfgang Krüger, Constance, Germany

Cardiac assist devices | Small Hall

Frank Klefisch, Berlin, Germany

08:00 – 09:00 | Large Hall

Session 3

Fluid resuscitation

Chair:

Mervyn Singer, London, United Kingdom;
Gunnar Elke, Kiel, Germany

Plasma transfusion for septic shock

Markus Weigand, Heidelberg, Germany

Balanced crystalloids better than saline

- **Pro:** Alexander Zarbock, Münster, Germany
- **Con:** Michael Bauer, Jena, Germany

09:00 – 09:30

Break

09:30 – 10:30 | Large Hall

Session 4

Selective digestive tract decontamination (SDD)

Chair:

Bernd Salzberger, Regensburg, Germany;
Wolfgang Krüger, Constance, Germany

The gut microbiome modulates body temperature in sepsis

John Marshall, Toronto, Canada

SDD update – standard of care?

- **Pro:** Marc Bonten, Utrecht, Netherlands
- **Con:** Ian Seppelt, Sydney, Australia

10:30 – 10:45

Break

10:45 – 11:45 | Large Hall

Session 5

Optimising anti-infective therapy

Chair:

Mathias Pletz, Jena, Germany;
Hortense Slevogt, Hanover, Germany

TDM for Beta-Lactam antibiotics

Jan De Waele, Ghent, Belgium

Monoclonal antibodies for Pseudomonas aeruginosa in the ICU

Jean Chastre, Paris, France

HSV-1 and CMV reactivation in sepsis and COVID-19

Stefan Hagel, Jena, Germany

11:45 – 12:00**Break****12:00 – 13:30****Lunch Symposia****Sepsis and beyond: complex challenges in infection management on the intensive care unit**

Large Hall

Supported by Pfizer Pharma GmbH**Chairs:**

Markus Weigand, Heidelberg, Germany

Update sepsis therapy - what needs to be considered?

Markus Weigand, Heidelberg, Germany

Diagnostic stewardship for multidrug-resistant pathogens

Jonathan Jantsch, Cologne, Germany

Scio nescio – the challenge of dosing anti-infective drugs during extracorporeal therapies

Jan Kielstein, Brunswick, Germany

From MRGN to AI – Emerging infectious challenges and opportunities in intensive care medicine

Wing Hall 1

Supported by MSD Sharp & Dohme**Chairs:**

Mathias Pletz, Jena, Germany

Treatment options for MRGN pathogens: overview and new data

Mathias Pletz, Jena, Germany

New recommendations for targeted treatment of MRGN: special view on pneumonia

Jessica Rademacher, Hanover, Germany

AI-based systems in intensive care medicine: fiction or soon daily routine?

Hartmuth Nowak, Bochum, Germany

Tailoring sedation for the septic, mechanically ventilated patient – prime time for Sedaconda

Seminar Room 1

Supported by Sedana Medical Germany GmbH**Chair:**Jean-Michel Constantin, Paris, France;
Kerstin Röhm, Ludwigshafen, Germany**The history and future of ICU sedation**

Peter Sackey, Stockholm, Sweden

Inhaled sedation in sepsis: from bench to bedside

Patrick Kellner, Lubeck, Germany

Scientific and clinical rationales for inhaled sedation in ARDS

Jean-Michel Constantin, Paris, France

12:00 – 13:00 | Seminar Room 3**REMAP-CAP: ITSC meeting**

(internal meeting)

12:00 – 13:30 | Small Hall**SepNet: General Assembly**

(internal meeting)

12:00 – 14:00 | Rank Foyer

Poster Sessions

Experimental sepsis research 1 (054 – 067)

Chairs: Marcin Osuchowski, Vienna, Austria;
Tomasz Skirecki, Warsaw, Poland

Experimental sepsis research 2 (068 – 082)

Chairs: Jesus F. Bermejo-Martin, Salamanca, Spain;
Ignacio Rubio, Jena, Germany

Experimental sepsis research 3 (083 – 099)

Chairs: Sebastian Weis, Jena, Germany;
Stefanie Flohé, Essen, Germany

Clinical sepsis research – diagnostics 1 (001 – 017)

Chairs: Achim Kaasch, Magdeburg, Germany;
Martin Witzgenrath, Berlin, Germany

13:30 – 14:00

Break

14:00 – 15:00 | Large Hall

Session 6

Early sepsis recognition

Chair:

André Scherag, Jena, Germany;
Hartmuth Nowak, Bochum, Germany

Is pre-symptomatic detection of sepsis possible?

Mervyn Singer, London, United Kingdom

Predicting sepsis severity at first clinical presentation

Hjalmar R. Bouma, Groningen, Netherlands

Phenotyping sepsis by AI

Azra Bihorac, Gainesville / Florida, United States

15:00 – 15:30

Break

15:30 – 16:30 | Large Hall

Session 7

Plasma exchange and sorbents

Chair:

Axel Nierhaus, Hamburg, Germany;
Alexander Brinkmann, Heidenheim, Germany

COVID-19 subphenotypes and differential treatment response to convalescent plasma

Manu Shankar-Hari, Edinburgh, Scotland

Therapeutic plasma exchange in sepsis

Sascha David, Zurich, Switzerland

Blood purification in septic patients: evidence and unanswered questions

Ricard Ferrer Roca, Barcelona, Spain

16:30 – 17:00

Break

17:00 – 18:00 | Large Hall

Session 8

Immunomodulation – advances and adaptations 1

Chair:

Thorsten Brenner, Essen, Germany;

Sebastian Weis, Jena, Germany

Epirubicin to promote disease tolerance in sepsis

Luís F. Moita, Oeiras, Portugal

Umbilical mesenchymal stromal cell therapy

Duncan Stewart, Ottawa, Canada

Macrophage activation-like syndrome (MALS) and immunoparalysis

Evangelos J. Giamarellos-Bourboulis, Athens, Greece

18:00 – 19:00 | Wing Hall 1

DSG: General Assembly

(internal meeting)

20:00 – open | Villa Haar, in the Park

Faculty Dinner

Featuring Bernd Smolarek, accordion

07:30 – 08:00

Sepsis Morning Rounds

My worst sepsis case

Community acquired pneumonia | Wing Hall 1

Sirak Petros, Leipzig, Germany

Haemato-Oncology | Wing Hall 2

Matthias Kochanek, Cologne, Germany

ARDS | Small Hall

Rolf Dembinski, Bremen, Germany

08:00 – 09:00 | Large Hall

Session 9

Immunomodulation – advances and adaptations 2

Chair:

Martin Witzenrath, Berlin, Germany;

Joerg C. Schefold, Bern, Switzerland

High dose Vitamin C – all over?

Francois Lamontaigne, Sherbrooke, Canada

Anti-C5a in sepsis and COVID-19

Alexander P J Vlaar, Amsterdam, Netherlands

TREM-1 modulation strategies

Bruno François, Limoges, France

09:00 – 09:30

Break

09:30 – 10:30 | Large Hall

Session 10

Immunomodulation – advances and adaptations 3

Chair:

Patrick Meybohm, Wurzburg, Germany;
Sebastian Stehr, Leipzig, Germany

Non-neutralizing adrenomedullin antibody

Matthijs Kox, Nijmegen, Netherlands

Human recombinant alkaline phosphatase on kidney function

Peter Pickkers, Nijmegen, Netherlands

Immune checkpoint inhibitors

Sachin Yende, Pittsburgh, United States

10:30 – 10:45

Break

10:45 – 11:45 | Large Hall

Session 11

Equipoise for ECMO in ARDS

Chair:

Konstanty Szudrzyński, Kraków, Poland;
Michael Sander, Giessen, Germany

ECMO for COVID-19 – evidence from observational studies

Martin Urner, Toronto, Canada

We need RCT's

- **Pro:** Alain Combes, Paris, France
- **Con:** Luciano Gattinoni, Goettingen, Germany

11:45 – 12:00

Break

12:00 – 13:30

Lunch Symposium

Biomarker update: diagnosis and prognosis of ICU patients with infections

Wing Hall 1

Supported by Thermo Fisher Scientific BRAHMS GmbH

Chair:

Mathias Pletz, Jena, Germany;
Michael Oppert, Potsdam, Germany

Biomarker diagnostics and prognostics for infections in emergency medicine

Michael Bauer, Jena, Germany

Applications for procalcitonin in thoracic and abdominal infections

Christian Eckmann, Hann. Münden, Germany

Targeted antibiotic stewardship in infectious disease intensive care patients

Jessica Rademacher, Hanover, Germany

12:00 – 13:30 | Rank Foyer

Poster Sessions

Clinical sepsis research – diagnostics 2 (018 – 026)

Chairs: Axel Nierhaus, Hamburg, Germany;
Dennis Nurjadi, Lubeck, Germany

Clinical sepsis research – diagnostics 3 (027 – 034)

Chairs: Hortense Slevogt, Hanover, Germany;
Joerg C. Schefold, Bern, Switzerland

Clinical sepsis research – therapeutics 1 (035 – 043)

Chairs: Patrick Meybohm, Wurzburg, Germany;
Gunnar Elke, Kiel, Germany

Clinical sepsis research – therapeutics 2 (044 – 052)

Chairs: Thorsten Brenner, Essen, Germany;
Sebastian Stehr, Leipzig, Germany

Prevention & long-term outcome 1 (100 – 107)

Chairs: Michael Bauer, Jena, Germany;
Matthias Kochanek, Cologne, Germany

Prevention & long-term outcome 2 (110 – 117)

Chairs: Frank Bloos, Jena, Germany;
Stefan Hagel, Jena, Germany

13:30 – 14:00

Break

14:00 | Large Hall

Poster Award Ceremony

14:00 – 15:00 | Large Hall

Hot Topic Session

Chair:

Markus Weigand, Heidelberg, Germany;
Michael Adamzik, Bochum, Germany

Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY - RCT

Giacomo Monti, Milan, Italy

2023 ESICM guidelines on acute respiratory distress syndrome

Luciano Gattinoni, Goettingen, Germany

Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP -RCT

Francois Lamontagne, Sherbrooke, Canada



Foto: Poster Sessions, Sepsis Update 2017

© Maik Schuck, Weimar GmbH

SPEAKERS & CHAIRS

Speakers and chairs

Michael Adamzik

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany

Djillali Annane

Réanimation médicale adulte, Hôpital Raymond-Poincaré, Paris, France

Michael Bauer

Klinik für Anästhesiologie und Intensivmedizin, Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany

Jan Beneš

Department of Anesthesiology and Intensive Care Medicine, Charles University in Prague | CUNI, Plzeň-Lochotín, Czech Republic

Jesus F. Bermejo-Martin

Instituto de Investigación Biomédica de Salamanca, University of Salamanca, Salamanca, Spain

Azra Bihorac

Medicine, Surgery and Anesthesiology, Intelligent Critical Care Center, University of Florida College of Medicine, Gainesville/Florida, United States

Sabine Bischoff

Stabsstelle Tierschutz, Universitätsklinikum Jena, Jena, Germany

Marc Bonten

Department of Epidemiology, Julius Center Research Program Infectious Diseases, Utrecht, Netherlands

Hjalmar R. Bouma

Department of Internal Medicine, Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

Thorsten Brenner

Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Essen, Germany

Josef Briegel

Klinik für Anästhesiologie Klinikum der Universität München, Munich, Germany

Alexander Brinkmann

Klinik für Anästhesie, Operative Intensivmedizin und spezielle Schmerztherapie, Klinikum Heidenheim, Heidenheim, Germany

Frank M. Brunkhorst

Zentrum für Klinische Studien, Universitätsklinikum Jena, Jena, Germany

Lina Carvahlo

Instituto de Anatomia Patológica, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal

Jean Chastre

Assistance Publique, Hôpitaux de Paris, Paris, France

Benjamin Glenn Chousterman

Dpt. Anaesthesiology and Critical Care Medicine, Université Paris Cité, Paris, France

Annika Claßen

University of Cologne | UOC · Division of Haematology, Immunology, Infectiology, Intensive Care and Oncology, Cologne, Germany

Alain Combes

Intensive Care Medicine, La Pitié-Salpêtrière Hospital, Paris, France

Jean-Michel Constantin

University Hospital Pitié-Salpêtrière, Sorbonne University, Clermont-Ferrand, France

Sascha David

Institut für Intensivmedizin, Universitätsspital Zürich, Zurich, Switzerland

Jan De Waele

Dept. of Critical Care Medicine, Ghent University Hospital, Gent, Belgium

Rolf Dembinski

Klinik für Intensiv- und Notfallmedizin, Klinikum Bremen-Mitte, Bremen, Germany

Lennie Derde

Intensive Care Medicine, UMC Utrecht, Utrecht, Netherlands

Christian Eckmann

Klinik f.Allgemein-, Viszeral- und Thoraxchirurgie, Klinikum Hann-Münden, Hann. Münden, Germany

Gunnar Elke

Klinik für Anaesthesiologie und Operative Intensivmedizin, Universitätsklinikum Kiel, Kiel, Germany

Ricard Ferrer Roca

Intensive Care Medicine, Vall d'Hebron General Hospital, Barcelona, Spain

Simon Finfer

George Institute for Global Health, 1 King St., Newtown, NSW 2042, Sydney, Australia

Stefanie Flohé

Klinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Essen, Essen, Germany

Bruno François,

Limoges Clinical Investigation Center, University Hospital of Limoges, Limoges, France

Luciano Gattinoni

Department of Anesthesiology, Emergency and Intensive Care Medicine, University of Göttingen, Goettingen, Germany

Herwig Gerlach

Deutsche Sepsis-Gesellschaft, Berlin, Germany

Evangelos J. Giamarellos-Bourboulis

4th Department of Medicine, ATTIKON University Hospital Athens, Athens, Greece

Waldemar Goździk

Department of Anaesthesiology and Intensive Therapy, Wrocław Medical University, Wrocław, Poland

Béatrice Grabein

Ludwig-Maximilians-Universität München, Klinische Mikrobiologie und Krankenhaushygiene, Campus Großhadern, Munich, Germany

Stefan Hagel

Institut für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena, Jena, Germany

Céline Heini

German Centre for the Protection of Laboratory Animals,
Federal Institute for Risk Assessment, Berlin, Germany

Verena Hörr

Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II,
Herzzentrum, AG Kardiovaskuläre Bildgebung, Bonn, Germany

Radmilo J. Jankovic

Anesthesiology and Reanimation Center, Clinical Center Niš,
Niš, Serbia

Milosz Jankowski

Internal Medicine, Jagiellonian University Kraków, Kraków, Poland

Achim Kaasch

Institut für Medizinische Mikrobiologie und Krankenhaushygiene,
Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany

Patrick Kellner

Klinik für Anästhesiologie und Intensivmedizin,
Universitätsklinikum Lübeck, Lübeck, Germany

Tilman Klassert

Dynamics of Respiratory Infections (DINF),
Helmholtz Centre for Infection Research, Brunswick, Germany

Frank-Rainer Klefisch

Intensivstation, Paulinen-Krankenhaus Berlin, Berlin, Germany

Matthias Kochanek

Klinik I für Innere Medizin, Internistische Intensivstation,
Universitätsklinikum Köln, Cologne, Germany

Martin Kolditz

Bereich Pneumologie, Medizinische Klinik 1, Universitätsklinikum
Carl Gustav Carus Dresden, Dresden, Germany

Matthijs Kox

Intensive Care Medicine, Radboud University Medical Centre,
Nijmegen, Netherlands

Stephanie Krämer

Versuchstierkunde und Tierschutz, Klinikum Veterinärmedizin,
Justus-Liebig-Universität Giessen, Giessen, Germany

Dorothee Kretschmer

Interfakultäres Institut für Mikrobiologie und Infektionsmedizin,
Universitätsklinikum Tübingen, Tübingen, Germany

Wolfgang Krüger

Klinik für Anästhesiologie, Intensivmedizin, Notfallmedizin und
Schmerztherapie, Klinikum Konstanz, Constance, Germany

Gunnar Lachmann

Department of Anesthesiology and Operative Intensive Care
Medicine (CCM, CVK), Charité Berlin & Berlin Institute of Health
(BIH), Berlin, Germany

Mitja Lainscak

Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, Slovenia

Francois Lamontaigne

Centre de recherche du CHU de Sherbrooke,
Sherbrooke, QC, Canada

John Marshall

Department of Surgery, University of Toronto, Toronto, Canada

Danny McAuley

Dentistry and Biomedical Sciences, Queen's University School
of Medicine, Belfast, United Kingdom

Patrick Meybohm

Klinik und Poliklinik für Anästhesiologie, Intensivmedizin,
Notfallmedizin und Schmerztherapie, Universitätsklinikum
Würzburg, Würzburg, Germany

Malgorzata Mikaszewska-Sokolewicz

Department of Anesthesiology and Intensive Care,
Medical University of Warsaw, Warsaw, Poland

Luís F. Moita

Innate Immunity and Inflammation,
Instituto Gulbenkian de Ciencia, Oeiras, Portugal

Zsolt Molnár

Department of Anaesthesiology and Intensive Therapy,
Semelweis University, Budapest, Hungary

Giacomo Monti

Department of Anesthesia and Intensive Care,
IRCCS San Raffaele Scientific Institute, Milan, Italy

Ute Neugebauer

Leibniz-Institut für Photonische Technologien Jena (IPHT),
Jena, Germany

Axel Nierhaus

Klinik für Intensivmedizin, Universitätsklinikum Hamburg-Eppendorf,
Hamburg, Germany

Hartmuth Nowak

Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie,
Universitätsklinikum Knappschafts-Krankenhaus Bochum GmbH,
Bochum, Germany

Dennis Nurjadi

Klinik für Infektiologie und Mikrobiologie, Universitätsklinikum Lübeck,
Lübeck, Germany

José Luis Oliveira

Institute of Electronics and Informatics Engineering of Aveiro
University of Aveiro, Aveiro, Portugal

Marcin Osuchowski

Experimentelle und Klinische Traumatologie,
Ludwig-Boltzmann-Institut, Vienna, Austria

Andreas Peschel

Interfakultäres Institut für Mikrobiologie und Infektionsmedizin,
Eberhard Karls Universität Tübingen, Tübingen, Germany

Sirak Petros

Interdisziplinäre Internistische Intensivmedizin,
Universitätsklinikum Leipzig, Leipzig, Germany

Peter Pickkers

Dpt. of Intensive Care, Radboud University, Nijmegen, Netherland

Romain Pirracchio

Dpt. of Anesthesia and Perioperative Medicine, Zuckerberg
San Francisco General Hospital and Trauma Center,
University of California, San Francisco, United States

Mathias Pletz

Institut für Infektionsmedizin und Krankenhaushygiene,
Universitätsklinikum Jena, Jena, Germany

Adrian Press

Klinik für Anästhesiologie und Intensivtherapie,
Universitätsklinikum Jena, Jena, Germany

Jessica Rademacher

Klinik für Pneumologie und Infektiologie,
Medizinische Hochschule Hannover, Hanover, Germany

Siegbert Rieg

Abteilung Infektiologie, Klinik für Innere Medizin II,
Universitätsklinikum Freiburg, Freiburg, Germany

Jordi Riera

Departament de Medicina Intensiva, Hospital Universitari Vall d'Hebron,
SODIR, Vall d'Hebron Institut de Recerca, Barcelona, Spain

Reimer Riessen

Dpt. für Innere Medizin, Internistische Intensivstation,
Universitätsklinikum Tübingen, Tübingen, Germany

Kerstin Röhm

Klinik für Anästhesie, interdisziplinäre Intensivmedizin und
Schmerztherapie, St. Mary and Anna Hospital, Ludwigshafen,
Germany

Peter Rosenberger

Universitätsklinik für Anästhesiologie und Intensivmedizin,
Universitätsklinikum Tübingen, Tübingen, Germany

Jan Rossaint

Klinik für Anästhesiologie, operative Intensivmedizin und Schmerz-
therapie, Universitätsklinikum Münster, Münster, Germany

Kathy Rowan

Chief Investigator, ICNARC, London, United Kingdom

Ignacio Rubio

FZL - FB Experimentelle Anästhesie, Universitätsklinikum Jena,
Jena, Germany

Peter Sackey

Chief Medical Officer at Sedana Medical, Associate professor
at Karolinska Institutet, Stockholm, Sweden

Bernd Salzberger

Abteilung für Krankenhaushygiene und Infektiologie,
Universitätsklinikum Regensburg, Regensburg, Germany

Michael Sander

Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Giessen, Justus-Liebig-Universität Giessen, Germany

Dorel Sandesc

Anestezie, Brol Medical Center, Timisora, Romania

Jörg C. Scheffold

Universitätsklinik für Intensivmedizin, Inselspital Bern, Bern, Switzerland,

André Scherag

Institut für Medizinische Statistik, Informatik und Datenwissenschaften, Universitätsklinikum Jena, Germany

Matthieu Schmidt

Service de Médecine Intensive Réanimation, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France

Brendon P. Scicluna

Department of Biomedical Science, Faculty of Health Sciences, University of Malta, Malta

Ian Seppelt

Critical Care and Trauma Division of The George Institute Sydney, Sydney, Australia

Manu Shankar-Hari

Translational Critical Care Medicine, Edinburgh Royal Infirmary, Edinburgh, Scotland

Mervyn Singer

Bloomsbury Institute for Intensive Care Medicine, University College Hospital, London, United Kingdom

Tomasz Skirecki

Department of Anesthesiology and Intensive Care, Centre of Postgraduate Medical Education, Warsaw, Poland

Hortense Slevogt

Medizinische Hochschule Hannover (MHH), Klinik für Pneumologie, Hanover, Germany

Alex Soriano

Department of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain

Sebastian Stehr

Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Universitätsklinikum Leipzig, Leipzig, Germany

Duncan Stewart

Ottawa Hospital Research Institute | OHRI · Sprott Centre for Stem Cell Research, Ottawa, Canada

Till Strowig

Helmholtz Zentrum für Infektionsforschung, Brunswick, Germany

Alexander Supady

Department of Medicine III, Interdisciplinary Medical Intensive Care, University of Freiburg, Freiburg, Germany

Alan Šustić

Department of Anesthesiology, Resuscitation and Intensive Care, University of Rijeka, Rijeka, Croatia

Konstanty Szudrzyński

Dpt. of Anaesthesiology and Intensive Care Medicine, University Hospital Warsaw, Warsaw, Poland

Martin Urner

Medical/Surgical Intensive Care Unit, University Health Network, Toronto General Hospital, Toronto, Canada

Greet Van den Berghe

Intensive Care Medicine Research Group, Dpt. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

François Vandenesch

Institut des agents infectieux, CHU de Lyon HCL - GH Nord-Hôpital de la Croix Rousse, Lyon, France

Alexander P. J. Vlaar

Amsterdam institute for Infection and Immunity, Amsterdam University Medical Center, Amsterdam, Netherlands

Ingrid Walter

Veterinärmedizinische Universität Wien, Vienna, Austria

Markus Weigand

Anästhesiologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Germany

Sebastian Weis

Translational Infection Medicine, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany

Martin Witzentrath

Medizinische Klinik m. S. Infektiologie und Pneumologie, Charité – Universitätsmedizin Berlin, Berlin, Germany

Sachin Yende

Critical Care Medicine and Clinical and Translational Science, VA Pittsburgh Critical Care, Pittsburgh, United States

Roman Záhorec

Department of Anesthesiology and Intensive Medicine, Comenius University Bratislava, Bratislava, Slovakia

Alexander Zarbock

Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie, Universitätsklinikum Münster, Münster, Germany

Vasileios Zochios

Department of Cardiothoracic Critical Care Medicine and ECMO Unit, Glenfield Hospital, University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom

AI Academy



Live Webinare
On-demand Webinare
Studien
CME Module
Podcasts



[www.pfizerpro.de/
AI-Academy](http://www.pfizerpro.de/AI-Academy)

DIE **INNOVATIVE** PFIZER
FORTBILDUNGSPLOTTFORM
IN DER **INFEKTILOGIE**



COMPANIES & EXHIBITORS

Lunch symposia

- ▶ Pfizer Pharma GmbH // 20.500€
- ▶ MSD Sharp & Dohme GmbH // 16.500€
- ▶ Sedana Medical Germany GmbH // 16.500€
- ▶ Thermo Fisher Scientific // 16.500€



Other sponsors

- ▶ Leila PRO // Lindgrün GmbH // 4.000€

Leila

Exhibitors

- ▶ Axon Lab AG // 5.400€
- ▶ Biocartis N.V. // 4.200€
- ▶ bioMérieux Deutschland GmbH // 3.600€
- ▶ Sphingotec GmbH // 2.700€
- ▶ AOP Orphan Pharmaceuticals Germany GmbH // 1.800€
- ▶ ARTCLINE GmbH // 1.800€
- ▶ Becton Dickinson Management GmbH & Co. KG // 1.800€
- ▶ Biotest AG // 1.800€
- ▶ CSL Behring GmbH // 1.800€
- ▶ CytoSorbents Europe GmbH // 1.800€
- ▶ Dr. Franz Köhler Chemie GmbH // 1.800€
- ▶ Dynamic 42 GmbH // 1.800€
- ▶ Fresenius Medical Care GmbH // 1.800€
- ▶ Gentian Diagnostics Asa // 1.800€
- ▶ Gilead Sciences GmbH // 1.800€
- ▶ InfectoPharm Arzneimittel GmbH // 1.800€
- ▶ Nova Biomedical GmbH // 1.800€
- ▶ Shionogi GmbH // 1.800€




Site map


■ Registration

■ Exhibitors

■ Catering



Park



Park

Exhibitors

Listed by booth number

- 16 Axon Lab AG
- 18 Shionogi GmbH
- 19 Dynamic 42
- 21 SphingoTec GmbH
- 23 Nova Biomedical GmbH
- 24 Infectopharm Arzneimittel Consilium GmbH
- 26 AOP Orphan Pharmaceuticals Germany GmbH
- 27 Gilead Sciences GmbH
- 31 CytoSorbents
- 33 Pfizer Pharma GmbH
- 34 Gentian Diagnostics Asa
- 35 Dr. F. Köhler Chemie GmbH
- 38 ARTCLINE GmbH
- 39 Fresenius Medical Care GmbH
- 40 Biotest AG
- 41 Biocartis
- 42+43 bioMérieux Deutschland GmbH
- 44 CSL Behring GmbH
- 45 MSD Sharpe & Dohme GmbH
- 46 Becton Dickinson Management GmbH & Co. KG
- 48+49 Sedana Medical Germany GmbH
- A REMAP-CAP/ECRAID
- B Deutsche Sepsis-Gesellschaft (DSG)
- C Center of Sepsis Control & Care (CSCC)
- D InfectoGnostics Forschungscampus Jena e.V.
- E Aktionsbündnis Patientensicherheit (APS) e.V.

In alphabetical order

- E Aktionsbündnis Patientensicherheit (APS) e.V.
- 26 AOP Orphan Pharmaceuticals Germany GmbH
- 38 ARTCLINE GmbH
- 16 Axon Lab AG
- 46 Becton Dickinson Management GmbH & Co. KG
- 41 Biocartis
- 42+43 bioMérieux Deutschland GmbH
- 40 Biotest AG
- C Center of Sepsis Control & Care (CSCC)
- 44 CSL Behring GmbH
- 31 CytoSorbents
- 35 Dr. F. Köhler Chemie GmbH
- B Deutsche Sepsis-Gesellschaft (DSG)
- 19 Dynamic 42
- 39 Fresenius Medical Care GmbH
- 34 Gentian Diagnostics Asa
- 27 Gilead Sciences GmbH
- D InfectoGnostics Forschungscampus Jena e.V.
- 24 Infectopharm Arzneimittel Consilium GmbH
- 45 MSD Sharpe & Dohme GmbH
- 23 Nova Biomedical GmbH
- 33 Pfizer Pharma GmbH
- A REMAP-CAP/ECRAID
- 48+49 Sedana Medical Germany GmbH
- 18 Shionogi GmbH
- 21 SphingoTec GmbH

Abstracts

POSTERSESSION 1

THURSDAY, SEPT 7, 12:00 – 14:00

Experimental sepsis research 1 (054 – 067)

Chairs: Marcin Osuchowski, Vienna, Austria;
Tomasz Skirecki, Warsaw, Poland

- 054:** Investigation of the prognostic value for metabolic erythrocyte profiling in a murine model of sepsis
Dustin Beyer, Jena, Germany
- 055:** Proteine Kinases C α and ζ , as mediators in excretory dysfunction of hepatocytes
Micha Banz, Jena, Germany
- 056:** RIPK3 promotor methylation is a hepatic protective mechanism against bile acid-induced inflammation and necroptosis
Jessica Hoff, Jena, Germany
- 058:** Bacterial polyphosphates mediate death and metabolic dysregulation during sepsis
Markus Bosmann, Mainz, Germany
- 059:** Comparing different sepsis scoring systems in experimental model of abdominal sepsis
Igor Plehutsa, Chernivtsi, Ukraine
- 060:** Virus-induced premature cellular senescence of the lung
Stefanie Deinhardt-Emmer, Jena, Germany
- 061:** Molecular interactions and immunomodulatory effects of stealth nanoparticles and C-reactive protein in sepsis
Aleksandar Rusevski, Jena, Germany
- 062:** Cloud-based system for histological image registration
Rodrigo Escobar Diaz Guerrero, Aveiro, Portugal
- 053:** Selective inhibition of conventional Protein kinase C isoforms prolongs survival and restores the host response in sepsis mice
Ling Xion, Jena, Germany
- 064:** (Wo)men & Mice – sex and age on the mouse intensive care unit
Ulrike Heinicke, Frankfurt, Germany

065: Anserin prevents methylglyoxal-induced capillary leakage in septic shock
Nadia Gallenstein, Heidelberg, Germany

066: Microbial metabolite dysregulation in obesity: A link between gut and alveolar sensing during Influenza A Virus infection
Franziska Hornung, Jena, Germany

067: Extracellular Vesicles and Endocannabinoid Signaling in Patients with COVID-19
Florian Brandes, Munich, Germany

Experimental sepsis research 2 (068 – 082)

Chairs: Jesus F. Bermejo-Martin, Salamanca, Spain;
Ignacio Rubio, Jena, Germany

068: Targeting the Granulocytic Defense against *A. fumigatus* in Healthy Volunteers and Septic Patients
Simon Dubler, Essen, Germany

069: Association of genetic polymorphisms of the danger receptor P2X7 with pneumonia, sepsis, and septic shock
Johann Guggemos, Ulm, Germany

070: Role of septic microparticles on cardiomyocytes
Dania Fischer, Heidelberg, Germany

071: Impact of major surgery on expression and binding of superordinate epigenetic regulators within the MHC-II region of circulating human monocytes: relevance for postoperative immunosuppression
Benedikt Siegler, Heidelberg, Germany

072: Monocytic immun checkpoints contribute differentially to septic immune paralysis
Jessica Löffler, Heidelberg, Germany

073: Major endothelial damage markers identified from hemadsorption filters derived from treated patients with septic shock – a novel role of Bikunin?
Marion Schneider, Ulm Germany

- 074:** Unveiling *S. aureus*-Induced Bone Deformation in a Mouse Model of Chronic Osteomyelitis through Fluorescence and Raman Imaging
Mandal Shibarjun, Jena, Germany
- 075:** Microglia mediate neurocognitive deficits by eliminating C1q-tagged synapses in sepsis-associated encephalopathy
Jonathan Wickel, Jena, Germany
- 076:** AMPK and mTORC1 signaling mediate calorie restriction-induced protection against inflammatory damage in hepatocytes
Harini Keerthana Suresh Kumar, Jena, Germany
- 077:** Telomerase RNA component deficiency exacerbates *S. aureus* pneumonia in mice
Yasmina Reißer, Jena, Germany
- 078:** Development of a Proximity-Ligation Assay for Quantifying Phosphorylated Toll-like Receptor 4 Activation in Sepsis: Implications for Patient Stratification and Therapeutic Targeting
Björn Koos, Bochum, Germany
- 079:** Studying mechanisms of endotoxin tolerance via proximity ligation analysis of nodal TLR4 signalling mediators
Florian Hickl, Jena, Germany
- 080:** AMPK and mTORC1 signaling mediate calorie restriction-induced protection against inflammatory damage in hepatocytes
Harini Keerthana Suresh Kumar, Jena, Germany
- 081:** Metamizole is a superior pain-reliever to Meloxicam with its minimal immune-inflammatory modulatory capacity in PCI murine sepsis
Na Liu, Jena, Germany
- 082:** The Inflammasome caspase-1 pathway drives lung fibrosis in COVID-19 ARDS
Konrad Peukert, Bonn, Germany

Experimental sepsis research 3 (083 – 099)

Chairs: Sebastian Weis, Jena, Germany;
Stefanie Flohé, Essen, Germany

- 083:** Biotransformation of sepsis-associated metabolites by intestinal microbiota in vitro
Ekaterina Chernevskaya, Moscow, Russia

- 084:** Visualization of pathogens and host cellular damage using electron microscopy
Sandor Nietzsche, Jena, Germany
- 085:** Prevention of PPAR γ -dependent conversion of Th2 cells as therapeutic concept in COVID-19 infection
Andreas von Knethen, Frankfurt, Germany
- 086:** Hyperspectral imaging is useful to non-invasively assess septic microcirculatory disorders in a mouse model
Lucas Tichy, Heidelberg, Germany
- 087:** ARDS in the preclinical mouse setting – are there age-specific differences?
Chantal Crispens, Frankfurt, Germany
- 088:** Altered AT2 cell functionality in TERC ko/ko mice leads to severe influenza A virus infection
Antje Häder, Jena, Germany
- 089:** Ontogenetic and functional heterogeneity of tissue resident macrophages during aging and systemic inflammation
Stephan Culemann, Jena, Germany
- 090:** Immune cell compartmentalization and function during sepsis
Stavroula Litsiou, Jena, Germany
- 091:** Effects of sepsis on the functional integrity of sensory neurons in mice
Beatrice Oehler, Heidelberg, Germany
- 092:** Exposure to nicotine containing e-cigarette vapor leads to endothelial barrier dysfunction and increased susceptibility to LPS in-vitro
Thorben Pape, Hanover, Germany
- 093:** Ex vivo characterization of the intra-epithelial lymphocytes (IEL) fraction from small intestine using Raman spectroscopy
Rustam Guliev, Jena, Germany
- 094:** Colonic luminal microbiota in early experimental abdominal sepsis
Ruslan Sydorчук, Chernivtsi, Ukraine
- 095:** Experimental morphological study on enteral dysfunction development in abdominal sepsis
Ruslan Sydorчук, Chernivtsi, Ukraine
- 096:** IMAGE-IN: A multidimensional 3D web visualizer for microscope imaging modalities
Yubraj Gupta, Aveiro, Portugal

- 097:** 23Na Magnetic Resonance Imaging in Sepsis-Induced Acute Kidney Injury
Ali Nahardani, Bonn, Germany
- 098:** Polymicrobial sepsis induces a hypometabolic response characterized by a distinct protein kinase signature
Wolfgang Vivas, Jena, Germany
- 099:** Comparative analysis of human dendritic cell responses to extra- and intracellular bacteria
Diana Dudziak, Erlangen, Germany

Clinical sepsis research – diagnostics 1 (001 – 017)

Chairs: Achim Kaasch, Magdeburg, Germany;
Martin Witzernath, Berlin, Germany

- 001:** Graphical analysis of microbial colonization and its variability of ICU patients
Marceli Lukaszewski, Walbrzych, Poland
- 002:** Circulating bioactive Adrenomedullin (bio-ADM) and lactate identify hydrocortisone responders among patients with sepsis – a post hoc analysis of the HYPRESS RCT
Caroline Neumann, Jena, Germany
- 003:** Scientific Update IgM/AIM (CD5L) Complex
Ulrich Bosch dos Santos, Bochum, Germany
- 004:** The concentration of apoptosis inhibitor of macrophages (AIM) protein is associated with 30-day survival in patients with COVID-19 sepsis
Dominik Ziehe, Bochum
- 005:** Changes in primary haemostasis under abdominal sepsis may determine postoperative intraabdominal adhesions
Ruslan Sydorчук, Chernivtsi, Ukraine
- 006:** Non-oncotic effects of albumin supplementation on sphingosine-1-phosphate regulated lymphocyte migration and endothelial cell barrier protection
Martin Winkler, Goettingen, Germany
- 007:** Sampling sites for blood culture diagnostic in septic patients in German emergency departments
Simon Oelsner, Greifswald, Germany
- 008:** Antigenemia and low anti-S1 antibodies at Emergency Room admission predict hospitalization in COVID-19 during an Omicron-predominant wave
Amanda de la Fuente, Salamanca, Spain
- 009:** Mixed Methods Study on Requirements for AI-Based Clinical Decision Support Systems Using the Medical Example of Sepsis: Study Design KI@work
Pascal Raszke, Essen, Germany
- 010:** Prognostic biomarkers in COVID-19 according to time since disease onset prior to hospitalization
Tamara Postigo Casado, Salamanca, Spain
- 011:** C-terminal AAT peptide biomarkers of sepsis / severe COVID-19 possess NET-inhibitory properties
Friedemann Börner, Jena, Germany
- 012:** Prediction of hospital mortality in critically ill COVID-19 patients (COVID-Hepa study) by C-terminal Alpha-1-Antitrypsin peptides
Franziska Scherr, Jena, Germany
- 013:** Clinical expert-assigned ground truth for sepsis prediction in neurosurgical and non-neurosurgical patients in the ICU
Franziska Holke, Mannheim, Germany
- 014:** GFR estimation based on Proenkephalin A 119-159: a new tool for assessing kidney function in patients undergoing RRT?
Peter Pickkers, Nijmegen, Netherlands
- 015:** Protein interaction assessing mitochondrial biogenesis as next generation biomarker in sepsis
Britta Marko, Bochum, Germany
- 016:** Assessment of albumin binding capacity in patients with acute renal failure
Gerd Klinkmann, Rostock, Germany
- 017:** Human cytomegalovirus latency is associated with reduced patient survival during sepsis
Matthias Unterberg, Bochum, Germany

POSTERSESSION 2

FRIDAY, SEPT 8, 12:00 – 13:30

Clinical sepsis research – diagnostics 2 (018 – 026)

Chairs: Axel Nierhaus, Hamburg, Germany;
Dennis Nurjadi, Lubeck, Germany

- 018:** Serum neurofilament light chain levels predict encephalopathy and outcome in community-acquired pneumonia
Barbora Bircak-Kuchtova, Jena, Germany
- 019:** A 29-mRNA host response classifier identifies bacterial infections following liver transplantation
Sebastian Decker, Heidelberg, Germany
- 020:** Suppression PCR-based selective enrichment sequencing (SUPSETS) for pathogen and antimicrobial resistance detection on cell-free DNA in sepsis
Mirko Sonntag, Stuttgart, Germany
- 021:** When Time to Result matters: Direct Rapid Susceptibility Testing of Sepsis Pathogens in Positive Blood cultures
Ulrike Schumacher, Ravensburg, Germany
- 022:** Availability of rapid microbiological testing technologies in German hospitals: a comparison between hospitals in rural areas and cities
Jacob Packmohr, Greifswald, Germany
- 023:** Altered sphingolipid metabolism in community acquired pneumonia is associated with prediction of unfavourable outcome
Ralf Claus, Jena, Germany
- 024:** The systemic inflammatory response syndrome for sepsis prediction and diagnosis in a polytrauma cohort: a systematic exploration of the contribution of individual criteria derived from a prospective algorithm
Verena Schneider-Lindner, Mannheim, Germany
- 025:** Sepsis in the first week after polytrauma is associated with reduced blood levels of soluble HVEM
Noah Schäfer, Mannheim, Germany
- 026:** Blood cell reactivity as a result of complicated mine-explosive injury
Ruslan Sydorчук, Chernivtsi, Ukraine

Clinical sepsis research – diagnostics 3 (027 – 034)

Chairs: Hortense Slevogt, Hanover, Germany;
Joerg C. Schefold, Bern, Switzerland

- 027:** Microbiota of infectious-inflammatory processes of soft tissues
Ruslan Sydorчук, Chernivtsi, Ukraine
- 028:** Unveiling Mutations Causing Carbapenemase-Independent Carbapenem Resistance for Molecular Diagnostics
Sara Madzgalla, Jena, Germany
- 029:** Mass-spectrometry analysis of exhaled breath condensate in SIRS/sepsis diagnostics of mechanically ventilated patients — preliminary results
Martin Müller, Prague, Czech Republic
- 030:** Platelet GPVI dysfunction as a sentinel biomarker in COVID-19 and early sepsis: Results from the PLAT-IS study
Lukas Johannes Weiss, Wurzburg, Germany
- 031:** Opening hours and transport distances to microbiological laboratories for blood culture analysis in 3 German states
Anne-Katrin Rachfall, Greifswald, Germany
- 032:** Th17 cells and IL17A in serum and BAL fluid in Covid19 and nonCovid19 severe community acquired pneumonia
Michal Moravec, Prague, Czech Republic
- 033:** Sepsis was the most frequent cause of death in ECMO treated COVID-ARDS – a single center experience
Daniel Thomas-Rüddel, Jena, Germany
- 034:** The Treg-attracting chemokine CCL1 allows discrimination between sterile inflammation and sepsis
Jennifer Müller, Munich, Germany

Clinical sepsis research – therapeutics 1 (035 – 043)

Chairs: Patrick Meybohm, Wurzburg, Germany;
Gunnar Elke, Kiel, Germany

- 035:** N-acetylcysteine in the treatment of patients with sepsis in the ICU: A meta-analysis
Mercedes Victoria Tanchuling, Manila, Philippines
- 036:** Impact of a low-carbohydrate nutrition in septic patients: the randomised controlled Keto-Sept trial
Tim Rahmel, Bochum, Germany

037: Analysis of the use of protocols regarding futile therapy in patients with sepsis/ septic shock treated in the Intensive Care Unit in years 2017–2022

Marek Welna, Wrocław, Poland

038: Immune paralysis in septic shock patients

Gerd Klinkmann, Rostock, Germany

039: Procalcitonin-Guided Antibiotic Therapy Shortens Length of Treatment and Is Associated with Improved Survival - A Systematic Review and Meta-Analysis

Marton Papp, Budapest, Hungary

040: Resistance to first-line empirical antibiotic treatment in septic patients admitted to the emergency department

Leonhard Maximilian von Beck, Budapest, Hungary

041: Albumin substitution in severe sepsis and septic shock

Eric Moegelin, Greifswald, Germany

042: Adaptive phagotherapy algorithms in treatment and prevention of nosocomial infections in critically ill patients

Ekaterina Chernevskaya, Moscow, Russia

043: Rationale and design of the COSMOS Registry: An international, prospective registry of CytoSorb® blood purification device in critically ill patients

Ricard Ferrer, Barcelona, Spain

Clinical sepsis research – therapeutics 2 (044 – 052)

Chairs: Thorsten Brenner, Essen, Germany;

Sebastian Stehr, Leipzig, Germany

044: Analysis of care pathways from the perspective of sepsis patients and their families – preliminary results from a qualitative interview study

Susanne Ullmann, Berlin, Germany

045: Immunomodulation by mesenchymal stem cell-derived exosomes and recombinant S1 protein of SARS-CoV2

Marion Schneider, Ulm, Germany

046: Establishment of a method to measure linezolid concentration in endotracheal aspiration in critically ill patients: A proof of concept trial

Diana Rebholz, Munich, Germany

047: Use of ECCO2R in Pneumocystis jirovecii pneumonia: elimination of CO2, meropenem, and vancomycin

Vassilissa Govorov, Munich, Germany

048: Biomarker-guided treatment of septic shock with enbarcimab – cut-off selection to overcome patient heterogeneity

Peter Pickkers, Nijmegen, Netherlands

049: An engineered IL-27a-based cytokine alleviates key drivers of sepsis mortality in ex vivo studies

Melanie Laschinger, Munich, Germany

050: „With great power comes greater predictability“ - Implementation of a machine learning algorithm to predict primary weaning failure in mechanically ventilated patients

Clemens Grimm, Goettingen, Germany

051: Severe hypocholesterolemia in patients with septic shock is attenuated by therapeutic plasma exchange

Sascha David, Zurich, Switzerland

052: Need for vasopressor therapy, increase of CRP levels and delayed arousal after cardiac arrest may facilitate extended antibiotic therapy to prevent sepsis

Maria Drayss, Wurzburg, Germany

Prevention & long-term outcome 1 (100 – 107)

Chairs: Michael Bauer, Jena, Germany;

Matthias Kochanek, Cologne, Germany

100: Auditing total medical expenses related to sepsis management

Iryna Sydorчук, Siegen, Germany

101: Sexual function and sexual satisfaction in survivors of severe sepsis and their partners: A pilot study

Alisa Shugaley, Jena, Germany

102: Differential Effects of an Internet-Based Cognitive-Behavioral Writing Therapy for Reducing PTSD Symptoms after Intensive Care: Results of a Per-Protocol Analysis

Johannes Reck, Jena, Germany

103: Microcirculatory oxygen extraction is associated with 180-day survival in sepsis

Timo Sturm, Mannheim, Germany

- 104:** Structural Requirements in Statutory Quality Assurance – Results of the Quality Indicator Development titled "Diagnosis, Therapy and Aftercare of Sepsis"
Stefanie Erckenbrecht, Berlin, Germany
- 105:** Perspective of healthcare providers on aftercare of sepsis survivors
Lea Draeger, Jena, Germany
- 106:** Mental health in the first year after sepsis – An analysis of German health claims data 2012–2015
Stefan Sell, Jena, Germany
- 107:** Health related quality of life and participation after inpatient rehabilitation of critically ill sepsis patients. A cohort study
Ulf Bodechtel, Dresden, Germany

Prevention & long-term outcome 2 (110 – 117)

Chairs: Frank Bloos, Jena, Germany;
Stefan Hagel, Jena, Germany

- 110:** Long-term outcomes of septic critically ill patients with and without COVID-19 – preliminary results from the prospective Comprehensive Sepsis Center Study Dresden-Kreischa
Felix Niebhagen, Dresden, Germany
- 111:** Does rabies blocks ICU-beds for sepsis in southern Malawi? A survey from 2012–2023
Gregor Pollach, Blantyre, Malawi
- 112:** Can rabies management release ICU-beds for sepsis in the world's resource poor countries?
Gregor Pollach, Blantyre, Malawi
- 113:** Our rabies / sepsis policy in Malawi: Do our medical students share our ethical opinions?
Gregor Pollach, Blantyre, Malawi
- 114:** Longitudinal Comparison of Vasopressin and Norepinephrine in Early Stage Septic Shock: A Propensity Score Caliper-Based Mahalanobis Distance Matching Study Using the Sepsis-3 Definition and MIMIC-IV Database
Clemens Grimm, Goettingen, Germany

- 115:** Therapeutic drug monitoring of CFTR modulators in adult cystic fibrosis patients
Alexandra Katharina Kunzelmann, Munich, Germany
- 116:** Puerperal and general sepsis as a complication for cesarean section in Malawi
Gregor Pollach, Blantyre, Malawi
- 117:** Treating sepsis in the Democratic Republic of Congo (DRC) – a challenge
Gregor Pollach, Butembo, République Démocratique du Congo



Contact

Deutsche Sepsis-Gesellschaft e.V.
Waldenserstraße 2-4, 10551 Berlin

info@sepsis-update.de
www.sepsis-update.de